Hepatocellular carcinoma (HCC) is a leading cause of death globally. Conventional chemotherapeutic agents are unable to penetrate cancerous hepatocytes completely and are toxic to non cancerous cells and tissues. This toxicity significantly compromises the therapeutic outcome of conventional chemotherapeutic agents which is also reflected in the high mortality of the disease. Nanotherapeutics have shed new light onto HCC treatment by enabling site-specific in vivo delivery of chemotherapeutics specifically to neoplastic hepatocytes without affecting normal hepatocytes. Thus, nanotherapeutics have shown considerable potential and there is tremendous impetus for rapid translation from the pre-clinical to the clinical domain to significantly prolong the survival in HCC. In Nanotherapeutics for the Treatment of Hepatocellular Carcinoma, authoritative experts of the field have explored the important aspects of nanotherapeutics against HCC. The book exhaustively, vividly and explicitly describes the molecular pathogenesis, diagnostic aspects and nanotherapy of HCC, while also highlighting the challenges of conventional therapy and the benefits of nanotherapeutics. Chapters of the book also cover recent investigations of nanotherapeutics against HCC, types of nanomedicines, recent patents, commercially available nanotherapeutics and a future perspective to give a comprehensive review of the topic to readers. In addition to these defining features, the book provides several references for further reading. The book is an ideal resource on HCC nanotherapeutics for medical and pharmacology postgraduate students, faculties, researchers, and biomedical scientists working on HCC and nanotherapy.

The Evolution of Radionanotargeting towards Clinical Precision Oncology is a remarkable book honoring Professor Kalevi Kairemo, who is known among academic and medical circles as a pioneer in novel radiolabeled therapeutics. This festschrift provides an overview of key advances in the field of radionanotargeting, and the directions for future development in patient care. Prof Kairemo's research is based on multiomics, which involves multiple elements: genomics, transcriptomics, proteomics, metabolomics, microbiomics, epigenomics, exposome, imaging, and precision medicine, which is reflected by the unique collection of articles presented. The articles start from the angle of radionanotargeting and theragnostics leading to imaging and therapy, which includes sections for thyroid cancer, head and neck cancer, genitourinary cancers and neuroendocrine neoplasms. Theragnostics, nanoparticles and precision oncology have also been covered in their own segments, while also giving a glimpse of research in metabolic imaging, cardiovascular radionuclide imaging, and bone therapies. The sequence of chapters demonstrates how, through Professor Kairemo's efforts, radionanotargeting has evolved to a practice changing therapeutic approach in the clinic, particularly in oncology. Finally, Professor Kairemo's own memoir, Seven decades in health care and memoirs from colleagues including a personal introduction to him with a photographic cavalcade reveals the world of a multitasking person with a multidisciplinary approach to science, that ushered his development of significant expertise across the fields of chemistry, biology, engineering, physics and clinical medicine. This book is excellent for medical historians, trainees and specialists in clinical and radiological oncology in expanding their understanding of the role of radionuclide imaging over the years, making it an ideal tribute that belongs in the library of anyone involved in the field.

Triple negative breast cancers (TNBC) are a biologically aggressive form of breast cancer and constitute approximately 10-15% of all breast cancer patients. Distant metastasis, lack of clinically targeted therapies and prognostic markers, makes the disease difficult to treat. Till now not much work has been carried out on this deadly disease. This book provides an overview of TNBC etiology, its treatment strategies and prognostic markers to identify the outcome of standard therapies. Signalling pathways namely cell proliferation, angiogenesis, invasion and metastasis, apoptosis, autophagy and others involved in complicating the disease have been described in the chapters to convey an understanding about the disease mechanisms. All the possible drugs either in pre-clinical or clinical stages have also been mentioned with data that depicts their efficiency in targeting altered genes. The book also introduces the reader to herbal medicine exhibiting high potency to target TNBC, their synthetic analogs used during chemotherapy and their ability to fight against chemoresistance. The concept of phytonanotechnology has also been discussed. The book helps create awareness among a broad range of readers about TNBC. It points to prioritizing the upgradation of health care facilities and re-designing future treatment strategies to provide maximum benefit to breast cancer patients.

Current Cancer Biomarkers is a comprehensive review on the status of biological markers for various types of cancer. It aims to update readers on current developments on the subject. The contents are divided into 5 sections covering a wide range of biomarkers and their diagnostic applications. The range of tumour biomarkers referenced here gives insights into molecular mechanisms behind cancer, including initiation, development, progression, prognosis, response to the therapeutic modalities, recurrence, and point-of-care application to detect cancer. Key features - Introduction of the basic features of cancer markers - Comprehensive and updated coverage of potential and effective biomarkers including genomic, epigenomic, transcriptomic, proteomic, cellular and morphologic factors - Information on biomarkers in many types of cancers including breast cancer, colorectal cancer, skin cancer, leukemia, liver cancer and prostate cancer - Applications of biomarkers in cancer diagnosis - Structured contents with easy-to-understand sections and headings - References for advanced readers The updated information about different aspects of cancer markers in the experimental and clinical setting will enrich the reader's understanding of the disease. The information serves as a resource to help in better management of cancer patients and understanding cancer biology when planning medical research projects. The book is intended as a reference for a diverse audience: biomedical science students, medical students, academics, researchers, clinicians and multidisciplinary teams involved in cancer management and research.

Nanotechnology has revolutionized cancer diagnosis and therapy through targeted drug delivery. Advances in protein engineering and materials science have led to the development of nanocarriers (NCs), which have helped overcome the challenges faced during conventional cancer treatment. These nanocarriers serve as an efficient transport module for drugs. Nano-drug delivery has emerged as a promising technology that results in early detection and better treatment of various cancers. The approved nanoparticles currently used in cancer treatment strategies include liposomes, dendrimers, polyplexes, solid lipid nano-carriers, etc. These nanocarriers shall provide a quick, safe, and cost-effective method in cancer therapy and management. This book contains thirteen chapters focusing on the treatment of various cancers, i.e., lung, breast, cervical, ovarian, colon, prostate, head and neck, etc., through nanocarrier drugs. The chapters include reviews on a wide variety of advanced data from existing and ongoing clinical research and major regulatory considerations. This reference book will greatly benefit undergraduate and postgraduate students, oncologists, pharmacists, and researchers involved in nanomedicine and nano-drug delivery.

Today, treatment options for cancer patients typically include surgery, radiation therapy, immunotherapy, and chemotherapy. While these therapies have saved lives and reduced pain and suffering, cancer still takes millions of lives every year around the world. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early-stage diagnosis. Molecular Targets and Cancer presents information about cancer diagnosis and therapy in a simple way. It covers several aspects of the topic with updated information on par with medical board levels. The book features contributions from experts and includes an overview of cancer from basic biology and pathology, classifications, surveillance, prevention, diagnosis, types of cancer, treatment and prognosis. The first part of this book introduces the reader to cancer epidemiology, genetic alterations in cancer, exogenous and endogenous factors in carcinogenesis, roles for growth factors in cancer progression, cell signaling in cancer, transcription factors in cancer, and cancer genetics and epigenetics. This comprehensive guide is a valuable resource for oncologists, researchers, and all medical professionals who work in cancer care and research.

Today, treatment options for cancer patients typically include surgery, radiation therapy, immunotherapy, and chemotherapy. While these therapies have saved lives and reduced pain and suffering, cancer still takes millions of lives every year around the world. Researchers are now developing advanced therapeutic strategies such as immunotherapy, targeted therapy, and combination nanotechnology for drug delivery. In addition, the identification of new biomarkers will potentiate early-stage diagnosis. Molecular Targets and Cancer presents information about cancer diagnosis and therapy in a simple way. It covers several aspects of the topic with updated information on par with medical board levels. The book features contributions from experts and includes an overview of cancer from basic biology and pathology, classifications, surveillance, prevention, diagnosis, types of cancer, treatment and prognosis. The second part of this book discusses specialized topics in clinical oncology which include the pathophysiology of various types of cancer, cancer screening, different types of cancer surgery, cancer stem cell-targeted immunotherapy, nanotechnology for precision medicine applications in cancer and cancer surveillance. This comprehensive guide is a valuable resource for oncologists, researchers, and all medical professionals who work in cancer care and research.

Gastrointestinal cancer is one of the most prevalent causes of cancer-related deaths in the world. Recent research demonstrates that phytochemicals are critical in preventing and managing gastrointestinal cancer. The increased intake of phytochemicals could reduce the risk of cancer by inhibiting cancer cell proliferation, inducing apoptosis and autophagy, and suppressing angiogenesis as well as cancer cell metastasis. These mechanisms are also known to counter Helicobacter pylori infection and modulate gut microbiota. There is preliminary data suggesting that daily supplementation with high doses of certain vitamins combined with conventional therapeutic agents may enhance their growth inhibitory effects on tumor cells and protect normal tissues against some of their toxic effects. This book attempts to fill gaps on the role of phytonutrients in the treatment of cancer in the gastrointestinal tract (GIT). It discusses the action of individual vitamins on cellular and molecular parameters and describes how vitamins inhibit protein kinase C activity, increase the production of certain growth factors, and modulate the expression of a number of oncogenes. The book is divided into 2 parts. The first part summarizes the pathophysiology of GIT cancers and introduces readers to anticancer phytonutrients. A chapter on the status of FDA approved nutraceuticals rounds up this section. The second part of the book provides a systematic review on the different plant derived chemicals that can be used to treat GIT cancer. Each chapter in this section focuses on a specific type of phytochemical agent and its molecular mechanisms relevant to the disease. This book will give the reader a holistic view of gastrointestinal cancer treatment and the value of natural compounds in developing functional food and drugs for preventive medicine.

Probiotics have been suggested to be involved in both prevention and treatment of various human cancers. Probiotics in Anticancer Immunity is a set of volumes in the Frontiers in Cancer Immunology series that explains biochemical mechanisms of anticancer immunity exerted by probiotics in various human cancers. It presents edited chapters focused on the evidence of probiotic use against human cancers through several animal and human studies. This volume of Probiotics in Anticancer Immunity consists of 11 chapters. The introductory chapters provide information about the link between gut microbiota and the host immune system in cancer and the general mechanisms of anticancer immunity exerted by probiotics. Subsequent chapters are focused on probiotics' anticancer immunity in specific cancers such as, skin cancer, stomach cancer, breast cancer, lung cancer, head and neck cancer, liver cancer, cervical and colon cancer. Key features - Gives a new dimensions and insight in the role of probiotics in anticancer immunity towards various human cancers - Provides several color figures and tables to clearly explain relevant information - Includes recent information with new insights and references - Meets the needs of basic (pre-clinical) and advanced clinical researchers and postgraduate scholars